[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cluster-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cluster-headache":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,73,100,131,163,190,212,240,268,300],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100433958","phase-2-clinical-trial-of-endoscopically-guided-injection-of-exparel-bupivacaine-for-the-treatment-of-craniofacial-pain-100433958",false,"NCT04930887","Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain","Prospective, Randomized, Double-blinded, Placebo-controlled, Cross-over Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) Towards the Ipsilateral Pterygopalatine Fossa for the Treatment of Craniofacial Pain","Inclusion Criteria:\n\n* Patients with a chief complaint of craniofacial pain (migraine, cluster headache, trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, paroxysmal hemicrania) who has Stanford Pain \\& ENT clinic visit\n\nExclusion Criteria:\n\n* age \\\u003C18 or \\>80\n* pregnant women\n* economically disadvantaged (not able to afford clinic visits\u002Ftreatments)\n* decisionally impaired (unable to obtain informed consent)\n* has allergy to bupivacaine\n* unable or unwilling to participate plans to participate in another clinical study at any time during this study","ALL","18 Years","80 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may positively impact craniofacial pain and functional outcomes, in patients who experience relief with the topical application of Lidocaine (routinely given prior to almost all ENT endoscopy).",[27,28,29,30,31,32],"Craniofacial Pain","Migraine","Cluster Headache","Trigeminal Autonomic Cephalgia","Sphenopalatine Ganglion Neuralgia","Paroxysmal Hemicrania","RECRUITING","2026-04-23",{"date":36,"type":37},"2026-04-27","ACTUAL",{"date":39,"type":37},"2023-02-01",{"date":41,"type":21},"2030-06",{"name":43,"class":44},"Stanford University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100278898","the-will-erwin-headache-research-center---cluster-headache-study-100278898","NCT02910323","The Will Erwin Headache Research Center - Cluster Headache Study","The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia","WEC1","Inclusion Criteria:\n\n* Diagnosis of a trigeminal autonomic cephalalgia according to the International Headache Classification including episodic cluster headache, chronic cluster headache, episodic paroxysmal hemicrania, chronic paroxysmal hemicrania, episodic short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), chronic SUNCT, episodic short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), chronic SUNA, and hemicrania continua. OR Diagnosis of a trigeminal neuralgia according to the International Headache Classification, including classical trigeminal neuralgia and symptomatic trigeminal neuralgia.\n* Able to provide HIPAA authorization to share prior medical records\u002Fimaging.\n\nExclusion Criteria:\n\n* Life expectancy less than 1 year, co-existing disease or other characteristic that precludes appropriate diagnosis of a trigeminal autonomic cephalalgia or trigeminal neuralgia.\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give informed consent.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Inclusion criteria is willingness to consent and be of age 18 and older",true,{"count":56,"type":21},1500,"OBSERVATIONAL","The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia is a prospective, multicenter, observational research network for subjects with Cluster Headache and\u002For Trigeminal Neuralgia.",[29,60,32,61,62,63],"Cluster Headaches and Other Trigeminal Autonomic Cephalgias","SUNCT","Hemicrania Continua","Trigeminal Neuralgia","2026-02-13",{"date":66,"type":37},"2026-02-18",{"date":68,"type":4},"2016-07-12",{"date":70,"type":21},"2035-12",{"name":72,"class":44},"The University of Texas Health Science Center, Houston",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100464211","phase-3-repeated-gon-injections-in-cch-100464211","NCT05324748","Repeated GON Injections in CCH","Repeated Corticosteroid Injections Around the Greater Occipital Nerve (GON) as Prophylactic Treatment in Chronic Cluster Headache","REGON","Inclusion Criteria:\n\n* Age ≥18 and ≤ 70 years\n* Chronic cluster headache (International Classification of Headache Disorders - third edition; ICHD-3)\n* Ictal pain must be always at the same side\n* ≥4 weekly attacks of cluster headache in the prospective one-month baseline observation period\n* On a stable regimen of cluster headache prophylactics for \\>4 weeks prior to onset of study treatment and agreeing not to increase the dose and not starting a new cluster prophylactic during the study period\n\nExclusion Criteria:\n\n* Contra-indication against, or current use of, corticosteroids\n* Occipital nerve stimulation (ONS)\n* Use of anticoagulation medication or a known bleeding disorder\n* Inability to use an electronic diary to monitor individual attacks and other items\n* Other headaches if the patient cannot reliably distinguish them from attacks of cluster headache\n* Current use of prophylactic medication for other headaches\n* Pregnancy","70 Years",{"count":83,"type":21},50,[85],"PHASE3","Background:\n\n\\- The effect of repeated GON-injections has never been studied in a double-blind randomized trial as a prophylactic therapy in a well-documented group of chronic patients. As such, (repeated) GON-injection has not yet found its place in current (inter)national treatment protocols for chronic cluster headache.\n\nObjectives:\n\n\\- The primary objective is to determine if repeated GON-injection result in effective control of cluster headache attacks for more days compared to placebo in chronic cluster headache.\n\nEligibility:\n\n\\- Patients will be selected from the LUMC (Leiden University Medical Center) and CWZ (Canisius Wilhelmina Hospital) chronic cluster headache populations, diagnosed based upon the ICHD-3.\n\nDesign:\n\n\\- Bi-centre, randomized, double-blind, placebo-controlled retention trial with a maximum follow-up of one year.",[29],[89],"GON-injection","2025-11-19",{"date":92,"type":37},"2025-11-24",{"date":94,"type":37},"2022-11-07",{"date":96,"type":21},"2026-06",{"name":98,"class":44},"Leiden University Medical Center",2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100537379","nvns-for-the-prevention-and-treatment-of-primary-headache-100537379","NCT06277063","nVNS for the Prevention and Treatment of Primary Headache","Noninvasive Vagus Nerve Stimulation for the Prevention and Treatment of Primary Headache: a Single-arm Single-center Clinical Trial.","Inclusion Criteria:\n\n1. Patients with migraine, cluster headache and tension-type headache were diagnosed according to Chinese Guidelines for the diagnosis and Treatment of Migraine (2022 edition) and Chinese Guidelines for the diagnosis and treatment of cluster headache (2022 edition).\n2. Age \\>=7 years old, \\\u003C=20 years old;\n3. Patients have experienced headache on 3-15 days per month in the past;\n4. Maintain a stable dose and frequency of medication and do not take new drugs during the course of participating in the trial;\n5. They volunteered to participate in the trial and signed informed consent.\n\nExclusion Criteria:\n\n1. History of secondary headache, aneurysm, intracranial hemorrhage, brain tumor, severe head trauma, drug abuse, addiction, syncope, or seizures;\n2. prior migraine-preventive surgery, cervical vagotomy, or implantation of an electronic or neurostimulator device;\n3. Simultaneous use of other devices (e.g., TENS devices, muscle stimulators);\n4. An implantable medical device in use, such as a pacemaker, hearing aid, or any implantable electronic device;\n5. underwent head and neck nerve block within the past 2 months;\n6. Opioid use (more than 2 days per month); Use of analgesics alone or non-steroidal anti-inflammatory drugs (more than 15 days per month); Or tamoxifen, ergots or combination analgesics (more than 10 days per month);\n7. Patients who underwent cervical vagotomy (cervical vagotomy);\n8. Pediatric patients (under 6 years old); Pregnant women;\n9. Patients with clinically significant hypertension, hypotension, bradycardia or tachycardia;\n10. Patients with congenital heart disease;\n11. Mental\u002Fcognitive disorders, etc.","7 Years","20 Years",{"count":20,"type":21},[111],"NA","This study is a single-center, single-arm study. All subjects will receive the same treatment.\n\nChildren and adolescents (7-20 years old) with migraine who met the inclusion criteria will be enrolled as subjects in the experimental group, and the changes in headache scores before and after the intervention will be compared. The intervention method is as follows: ictal intervention, in which subjects will be evaluated for headache improvement after a short intervention during an acute exacerbation. By wearing a vagus stimulator, the stimulating electrode will be located in the concha region rich in vagus nerve fiber endings, and the appropriate stimulation intensity will be adjusted for stimulation.\n\nTherefore, this study will verify the effect of nVNS on the acute treatment of primary headache in children and adolescents. Based on the electrocardiogram and electromyography indicators during the intervention process of nVNS, an objective evaluation system for the improvement of headache by nVNS is established, and the role of stimulation parameters on the effect is further explored to realize the optimization of parameters.",[114,115,116,29,117],"Primary Headache","Migraine in Adolescence","Migraine in Children","Tension Headache",[119,120,121],"Primary headache","Adolescents","Noninvasive vagus nerve stimulation","2025-08-06",{"date":124,"type":37},"2025-08-12",{"date":126,"type":37},"2024-12-05",{"date":128,"type":21},"2026-12-30",{"name":130,"class":44},"Nanfang Hospital, Southern Medical University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":54,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":142,"studyType":57,"phases":4,"briefSummary":143,"conditions":144,"keywords":151,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100434650","china-headache-and-vertigo-registry-study-100434650","NCT04939922","China Headache and Vertigo Registry Study","CHRS","Inclusion Criteria:\n\n* Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.\n* Male or female participants ages 4 to 99 years.\n* Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches.\n* Patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).\n\nExclusion Criteria:\n\n* Patients who were unable to complete scales such as headache diary.\n* Patients denied or unable to be admitted for long-term follow-up.","4 Years","99 Years",{"count":141,"type":21},10000,"30 Years","In the Chinese Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.",[145,146,28,147,29,148,149,150],"Headache Disorders, Primary","Headache Disorders, Secondary","Tension-Type Headache","Vertigo, Constant","Vestibular Migraine","Fibromyalgia",[28,152,153,149,150],"Headache Disorders","Vertigo","2025-07-22",{"date":156,"type":37},"2025-07-25",{"date":158,"type":37},"2017-06-12",{"date":160,"type":21},"2050-12-12",{"name":162,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":170,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":45},"100583895","pulsed-radiofrequency-combined-with-platelet-rich-plasma-applied-to-the-sphenopalatine-ganglion-in-treating-episodic-cluster-headache-100583895","NCT06882278","Pulsed Radiofrequency Combined With Platelet-Rich Plasma Applied to the Sphenopalatine Ganglion in Treating Episodic Cluster Headache","Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet-Rich Plasma Applied to the Sphenopalatine Ganglion in Treating Episodic Cluster Headache: A Study Protocol for a Multi-Center, Prospective, Open-Label, Propensity Score Match Cohort Study","Inclusion Criteria:\n\n1. The diagnosis of ECH is confirmed according to the diagnostic criteria of the International Classification of Headache Disorders third edition 3 (Table 2), and the patient is within five days of the current cluster period；\n2. The patient's age is between 18 and 70 years;\n3. Patients have had ≥2 bouts previously, ≥4 typical (treated or untreated) attacks per week and usual bouts should last 4 weeks;\n4. The patient's pain condition remains the same after preventive therapy with drugs available in our hospital such as verapamil, topiramate, lithium or steroids, or there is a reduction of less than 50% in the intensity and frequency of headache attacks, the duration of each attack and the dosage of auxiliary analgesic drugs used.\n\nExclusion Criteria:\n\n1. Have atypical features: absence of cranial autonomic symptoms, post-traumatic onset, cluster-tic syndrome;\n2. Abnormalities in blood measurements, liver and kidney function, blood glucose, coagulation, electrocardiography or chest radiography;\n3. Infection at the puncture site;\n4. Previous mental illness;\n5. Previous history of narcotic drug abuse;\n6. Prior anticoagulant or antiplatelet therapy;\n7. An implantable pulse generator;\n8. Previous history of invasive treatments such as pterygopalatine ganglion radiofrequency thermocoagulation and chemical destruction;\n9. Current pregnancy or breast feeding.",{"count":171,"type":21},242,"Cluster headache (CH) is one of the most severe pain accompanied by ipsilateral autonomic symptoms such as lacrimation and conjunctival injection. CH can be categorized into episodic cluster headache (ECH), chronic cluster headache (CCH), and probable CH. Intervention for CH requires a multifaceted and early approach and varies due to the heterogeneity of patients, which makes it difficult to formulate appropriate treatment plan, and the minimally invasive interventional therapy between drug and surgical treatment is still worth looking forward to.\n\nThe pterygopalatine ganglion, also known as SPG, is a essential proportion in activation of cortical structures and plays an important role in the pathogenesis of CH attacks, which makes it the potential therapeutic target in drug-resistant CH. Percutaneous pulsed radiofrequency (PRF) at SPG is a minimally destructive treatment which shows efficacy, safety, and repeatedly efficacy for refractory CH. PRF is a reliable alternative with few neurological side effects and complications for patients who have not responded to conservative treatment. However, the long term pain relieve is not satisfying. Platelet-rich plasma (PRP) is an autologous blood-derived product of 3 times concentrated platelet above average levels, which contains many growth factors, cytokines, chemokine, and cell-adhesion molecules, therefore function in the activation and synthesis of healing process, tissue proliferation and regeneration. Researches by Michno etc. and Giaccari etc. have proved that PRP combined with PRF therapy may provide more effective outcome than PRF alone in treatment of neuralgia, but whether the combined therapy can improve the efficacy of CH treatment is not clear. ECH occurs in 90% of the CH patients. The investigators assume that PRP combined with PRF acting on SPG might have better therapeutic effect on ECH than PRF alone, by giving combined treatment or PRF therapy alone according to patients willingness, the investigators plan on conducting this prospective trail to compare the clinical efficacy and safety of PRP combined with PRF versus PRF alone.",[29,174,175],"Pain Management","Episodic Cluster Headache",[175,177,178,179],"Pain management","Pulsed Radiofrequency","Platlet-rich Plasma","NOT_YET_RECRUITING","2025-03-20",{"date":183,"type":37},"2025-03-24",{"date":185,"type":21},"2025-05-01",{"date":187,"type":21},"2029-05-01",{"name":189,"class":44},"Beijing Tiantan Hospital",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":99},"100557633","efficacy-of-light-therapy-in-treatment-of-chronic-cluster-headache-100557633","NCT06540651","Efficacy of Light Therapy in Treatment of Chronic Cluster Headache","Proof-of-concept Study on the Efficacy of Light Therapy in the Prophylactic Treatment of Chronic Cluster Headache","LUMIAVFc","Inclusion Criteria:\n\n* Male or female, of 18 years years old or more;\n* Diagnosis of chronic cluster headache according to ICHD-3 criteria;\n* Number of seizures during baseline equal to at least 24;\n* Stability of prophylactic treatment for at least 1 month and commitment not to change it for the duration of the study;\n* Patient affiliated to the French social security system.\n* Patient who understands and speaks French correctly;\n* Patient who has given free and informed written consent.\n\nExclusion Criteria:\n\n* Contraindication to the use of light therapy: use of a photosensitizing treatment;\n* Ophthalmological history: cataract, macular degeneration, glaucoma, retinitis pigmentosa;\n* Patients who work at night;\n* Other neurological, psychiatric or developmental pathologies considered incompatible with the study;\n* Background treatment of cluster headache with melatonin;\n* Persons protected by articles L1121-5, L1121-6 and L1121-8 of the French Public Health Code (pregnant or breast-feeding women, persons deprived of their liberty by judicial decision, socially vulnerable persons, adults incapable or unable to express their consent).",{"count":199,"type":21},48,[111],"Cluster headache is a primary headache. The chronic form of the disease is often difficult to treat. It is now considered a chronobiological disease. This chronobiological character is based on clinical, biological and radiological arguments.\n\nThis study focuses on the use of light therapy in cluster headache. Light therapy has already been used in the treatment of other chronobiological diseases, such as seasonal depression, but also recently in the therapy of other primary headaches (such as migraine). Its aim is to re-adjust chronobiological rhythms, and it therefore seems worth testing in the chronic form of cluster headache.\n\nLight therapy is delivered to the patient using a consumer electronics device.The main objective is to evaluate the prophylactic efficacy of light therapy in patients with chronic cluster headache.",[29],"2025-03-13",{"date":205,"type":37},"2025-03-17",{"date":207,"type":37},"2025-02-06",{"date":209,"type":21},"2027-05-05",{"name":211,"class":44},"Assistance Publique Hopitaux De Marseille",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":45},"100345701","phase-2-lysergic-acid-diethylamide-lsd-as-treatment-for-cluster-headache-100345701","NCT03781128","Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache","Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study","LCH","Inclusion Criteria:\n\n* Age ≥ 25 and ≤ 75 years\n* Chronic cluster headache (according to the International Headache Society (IHS) criteria) OR\n* Episodic cluster headache (according to the IHS criteria) with recurrent predictable episodes lasting approximately 2 months and expected ongoing cluster period for at least one month beyond the inclusion\n* Attacks respond to oxygen\n* Sufficient understanding of the study procedures and risks associated with the study\n* Participants must be willing to adhere to the study procedures and sign the consent form\n* Participants are willing to abstain from taking preventive and abortive medication (except from oxygen) long enough before and after the LSD\u002Fplacebo treatment session to avoid the possibility of a drug-drug interaction\n* Participants are willing to refrain from taking any psychiatric medications during the experimental session period. If they are being treated with antidepressants, lithium or are taking anxiolytic medications on a fixed daily regimen, such drugs must be discontinued long enough before the LSD\u002Fplacebo treatment session to avoid the possibility of a drug-drug interaction.\n* Participants must also refrain from the use of any psychoactive drugs and caffeine within 24 hours of each LSD\u002Fplacebo treatment session. They must agree not to use nicotine for at least 2 hours before and 6 hours after each dose of LSD. They must agree to not ingest alcohol-containing beverages for at least 1 day before each LSD treatment session. Non-routine medications for treating breakthrough pain taken in the 24 hours before the LSD treatment session may result in rescheduling the treatment session to another date, with the decision at the discretion of the investigators after discussion with the participant.\n* Participants must be willing not to drive a traffic vehicle or to operate machines within 24 hours after LSD\u002Fplacebo administration.\n\nExclusion Criteria:\n\n* Other forms of headache attacks (migraine, paroxysmal hemicranias, shortlasting unilateral neuralgiform headache attacks with conjunctival injection, tearing, sweating and rhinorrhea (SUNCT) or with cranial autonomic symptoms (SUNA))\n* Women who are pregnant, nursing or of child-bearing potential and are not practicing an effective means of birth control (double-barrier method, i.e. pill\u002Fintrauterine device and preservative\u002Fdiaphragm)\n* Past or present diagnosis of a primary psychotic disorder. Subjects with a first degree relative with psychotic disorders are also excluded.\n* Past or present bipolar disorder (DSM-IV).\n* Current substance use disorder (within the last 2 months, DSM-V, except nicotine).\n* Somatic disorders including severe cardiovascular disease, untreated hypertension (systolic blood pressure \\> 160mmHg without treatment, systolic blood pressure \\> 140 mmHg with treatment), severe liver disease (liver enzymes increase by more than 5 times the upper limit of normal) or severely impaired renal function (estimated creatinine clearance \\\u003C30 ml\u002Fmin), or other that in the judgement of the investigators pose too great potential for side effects.\n* Weight \\\u003C 45kg\n* Participation in another clinical trial (currently or within the last 30 days)\n* Participants taking higher steroid doses (\\>10mg\u002Fd) over a longer time period (\\>2 weeks), as this would require tapering\n* Use of immunomodulatory agents (i.e. azathioprine) in the past 2 weeks\n* Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks","25 Years","75 Years",{"count":223,"type":21},30,[24],"Background: After no official research in humans in the last 40 years, research and therapeutic uses of the serotonergic psychedelic lysergic acid diethylamide (LSD) are now re-recognized and include its use in brain research, alcoholism, anxiety associated with terminal illness, and treatment of headache disorders. Specifically, LSD has been reported to abort attacks, to decrease frequency and intensity of attacks, and to induce remission in patients suffering from cluster headache (CH).\n\nObjective: To investigate the effects of an oral LSD pulse regimen (3 x 100 µg LSD in three weeks) in patients suffering from CH compared with placebo.\n\nDesign: Double-blind, randomized, placebo-controlled two-phase cross-over study design.\n\nParticipants: 30 patients aged ≥ 25 and ≤ 75 years with chronic or episodic CH with predictable periods lasting approximately 2 months and attacks responding to oxygen.\n\nMain outcome measures: Changes in frequency and intensity of CH attacks assessed with a standardized headache diary Significance: CH is often rated as the most painful of all primary headaches, which not only causes significant disability, but is also associated with enormous personal, economic, and psychiatric burden. At the moment, there is no specific treatment available for CH, but serotonergic compounds represent an important drug class, especially in the abortive management of cluster attacks. However, there is a need for new treatment approaches, as CH is also often insufficiently managed with available medication. This study will evaluate the potential benefit and safety of a treatment with LSD for patients with CH.",[29],[228,229,230,231],"lysergic acid diethylamide (LSD)","serotonin","hallucinogen","cluster headache",{"date":233,"type":37},"2025-02-07",{"date":235,"type":37},"2019-01-02",{"date":237,"type":21},"2025-12",{"name":239,"class":44},"University Hospital, Basel, Switzerland",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100358270","phase-3-botulinum-toxin-type-a-blockade-of-the-sphenopalatine-ganglion-in-treatment-refractory-chronic-cluster-headache-100358270","NCT03944876","Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache","BASIC","Inclusion Criteria:\n\n1. Informed and written consent.\n2. Male or female, 18-85 years of age\n3. Headache attacks fulfilling the International Classification of Headache Disorders (ICHD) III criteria for chronic cluster headache (CCH) 3.1.2.\n4. Dominant headache laterality with ≥ 80% of cluster headache attacks on one side.\n5. Subject reports an average of ≥ 4 cluster attacks\u002Fweek on the side of their dominant headache laterality in the 3 months prior to inclusion and in the baseline period.\n6. The condition is pharmacologically refractory defined as suboptimal effect or intolerable side effects or contraindication for verapamil or lithium or suboccipital steroid injection.\n7. Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during the whole study period.\n8. Subject is able to differentiate concomitant headaches from cluster headache.\n9. In case of women of childbearing potential (WOCBP) they have to be using highly effective contraception in a period of 4 weeks after injection.\n10. Ability to understand study procedures and to comply with them for the entire length of the study\n\nExclusion Criteria:\n\n1. Subject has had a change in type, dosage or dose frequency of preventive headache medications ≥ two weeks prior to baseline\u002Fscreening or 5 half-lives, whichever is longer.\n2. Subject currently treated with occipital nerve stimulation, deep brain stimulation or other implantable device, that have changed parameters in the last month, or are unable to keep parameters stable throughout the study.\n3. Current or previous treatment with implanted medical devices targeting the SPG\n4. Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period, eg. prior to IMP administration.\n5. Non-responder to both oxygen and triptan.\n6. Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study drug administration or 5 half-lives, whichever is longer.\n7. Subject is currently participating or has participated in the last 3 months in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.\n8. Allergy or hypersensitivity reactions to marcaine, lidocaine, xylocaine, adrenaline, any botulinum toxin or similar substances.\n9. Abuse of drugs or alcohol.\n10. Use of opioids for ≥10 days per month.\n11. Treatment with pharmacological substances that may interact with BTA (aminoglycosids, spectinomycin, neuromuscular blockers, both depolarizing agents (such as succinylcholine) or non-depolarizing (tubocurarine derivates), lincosamides, polymyxins, quinidine, magnesium sulfate or anticholinestases.).\n12. WOCBP that do not adhere to the requirements for HEC, as noted in inclusion criteria 9 and outlined in section 3.3.\n13. Pregnancy or breastfeeding in the study period\n14. Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned injection site that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.\n15. Facial anomaly or trauma which renders the procedure difficult.2\n16. Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms.\n17. Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months.\n18. Patients exhibiting a high degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.\n19. Patients with comorbid psychiatric disorders with psychotic or other symptoms making compliance with the study protocol difficult, at the discretion of the investigator.\n20. Patient with active infectious disease or infections that warrants special infection control measures, such as human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection.\n21. Patient with disorders that are known contraindication for Botox® treatment, especially neuromuscular disorders such as motorneuron disorders and myasthenic syndromes\n22. Subject has had previous radiofrequency ablation, balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the ipsilateral trigeminal ganglion or any branch of the trigeminal nerve.\n23. Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the ipsilateral SPG.\n24. Subject has had blocks of short-acting anaesthetics of the ipsilateral SPG in the last 3 months.\n25. Subject has undergone onabotulinumtoxinA injections of the head and\u002For neck in the last 3 months.\n26. Subject is anticipated to require any excluded medication, device, or procedure during the study.\n27. Subject has a history of bleeding disorders and in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.\n28. Subject has a history of coagulopathy.\n29. Subject is unable to stop antithrombotic medication, eg. anticoagulants and\u002For antiplatelet therapy, before procedure.\n30. The subject has been diagnosed with another trigeminal autonomic cephalalgia or trigeminal neuralgia.\n31. The patient cannot participate or successfully complete the study, in the opinion of their healthcare provider or the investigator, for any of the following reasons:\n\n    * mentally or legally incapacitated or unable to give consent for any reason.\n    * in custody due to an administrative or a legal decision, under tutelage, or being admitted to a sanatorium or social institution.\n32. The patient is a study centre employee who is directly involved in the study or the relative of such an employee.","85 Years",{"count":249,"type":21},112,[85],"Cluster headache is a primary headache condition characterized by clusters of one-sided, high-intensity pain attacks. The headache may be episodic or chronic. Treatment options are limited and their effects unsatisfactory. An important nerve pathway involved in the pain attacks has a switching station at the sphenopalatine ganglion (SPG) located in the depth of the facial bones. SPG is a known therapy target for cluster headache. The area can be identified on CT images, but is difficult to access due to its location. Thus, the Multiguide navigation system has been developed to enable precise delivery of the drugs that target SPG activity. In Trondheim, two phase 1 \u002F Phase 2 study have been carried out using botulinum toxin A (Botox®) against SPG in patient with chronic cluster headache and chronic migraine. The results indicate that such a treatment strategy is safe and beneficial. The current study is a randomized, placebo-controlled, triple-blinded study to investigate whether precise single-injection of botulinum toxin A reduces the frequency of attacks in chronic cluster headache .",[29],[254,255,256,257],"Botulinum Toxin Type A","Sphenopalatine Ganglion Block","Autonomic Nerve Block","Injections","2024-11-15",{"date":260,"type":37},"2024-11-19",{"date":262,"type":37},"2019-11-01",{"date":264,"type":21},"2025-09",{"name":266,"class":44},"Norwegian University of Science and Technology",5,{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":45},"100554764","role-of-specific-micrornas-in-cluster-headache-100554764","NCT06503328","Role of Specific microRNAs in Cluster Headache","Role of Specific microRNAs in Cluster Headache: Implications for Disease Phenotype and Neuropeptide Expression","5*1000","\\- Healthy Controls\n\nInclusion Criteria:\n\n* age between \\>18 and \\\u003C65 years\n\nExclusion Criteria:\n\n* diagnosis of primary and\u002For secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension type headache is allowed)\n* diagnosis of neurological disorders\n* diagnosis of medical conditions considered clinically relevant by the researcher\n* pregnant and lactating women\n* taking NSAIDs, triptans or opiates in the previous 24 hours\n* Episodic Cluster Headache\n\nInclusion Criteria:\n\n* diagnosis of Episodic Cluster Headache according to ICHD-III criteria (at least 1 year at screening)\n* age between \\>18 and \\\u003C65 years of both genders\n\nExclusion Criteria:\n\n* concomitant diagnosis of other primary and\u002For secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed)\n* diagnosis of other neurological disorders\n* diagnosis of medical conditions considered clinically relevant by the researcher\n* diagnosis of chronic pain syndrome of any nature\n* pregnant and lactating women\n* use of substances of abuse\n* Chronic Cluster Headache\n\nInclusion Criteria:\n\n* diagnosis of Chronic Cluster Headache according to ICHD-III criteria (at least 1 year at screening)\n* age between \\>18 and \\\u003C65 years of both genders\n\nExclusion Criteria:\n\n* concomitant diagnosis of other primary and\u002For secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed)\n* diagnosis of other neurological disorders\n* diagnosis of medical conditions considered clinically relevant by the researcher\n* diagnosis of chronic pain syndrome of any nature\n* pregnant and lactating women\n* use of substances of abuse","65 Years",{"count":278,"type":21},100,"Cluster headache (CH) is a primary headache included in the trigeminal autonomic cephalalgias (TACs) according to the International Calssification of Headache Disorder, Third Edition. CH is characterized by a multifaceted and incompletely understood pathophysiology. Recent experimental evidence has increasingly emphasized the role of specific microRNAs (miRNAs) in the pathophysiology of primary headaches, including migraine.\n\nIn a recent study, we observed an upregulation in the gene expression of two miRNAs, miR-382-5p and miR-34a-5p, in peripheral blood mononuclear cells (PBMCs) of subjects with chronic migraine (CM). These miRNAs are involved in inflammation modulation and the release of γ-aminobutyric acid (GABA). Notably, this upregulation correlated with the migraine phenotype and its severity.\n\nSeveral neuropeptides have been established to play an active role in CH. Studies by the Danish group have demonstrated that intravenous administration of CGRP, PACAP, or VIP can induce CH attacks in at least 50% of participants in the active phase of the disease.\n\nHowever, no data currently exists regarding the potential involvement of miRNAs in CH. Given this context, the primary aim of this study is to investigate the gene expression of specific miRNAs (miR-382-5p, miR-34a-5p, and miR-155) in PBMCs and plasma levels of neuropeptides (CGRP, PACAP, VIP) in subjects with episodic CH in the active phase (eCH-act), episodic CH in the remission phase (eCH-rem), chronic CH (cCH), and healthy control subjects (HCs).",[29],[282,283,284,285,286,287,288,289,290,28],"MicroRNA","miR-34a-5p","miR-155","miR-382-5p","Peripheral blood mononuclear cells","CGRP","PACAP","VIP","Headache","2024-07-09",{"date":293,"type":37},"2024-07-16",{"date":295,"type":37},"2023-03-01",{"date":297,"type":21},"2025-06-30",{"name":299,"class":44},"IRCCS National Neurological Institute \"C. Mondino\" Foundation",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":45},"100514420","a-close-examination-of-patient-experiences-in-cluster-headache-clinical-research-100514420","NCT05978258","A Close Examination of Patient Experiences in Cluster Headache Clinical Research","An Observational Study Assessing the Experience of Patients Undergoing Active Cluster Headache Clinical Trials","Inclusion Criteria:\n\n* Patient has been diagnosed with cluster headache\n* Patient has access to a home internet connection in order to provide regular updates through the course of the study\n* Participant must be 18 years of age or older\n\nExclusion Criteria:\n\n* Patient has an ECOG score of 4 or higher\n* Patient is not able to provide consistent digital updates as per study requirements\n* Patient does not complete or agree to terms outlined in the Informed Consent Form",{"count":308,"type":21},500,"Historically, participation in clinical studies is highly skewed towards particular demographic groups of people.\n\nThis research will invite several participants to gather a wide range of information on clinical trial experiences for cluster headache patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of cluster headache.\n\nThe data collected from this study will help improve future outcomes for all cluster headache patients as well as those in under-represented demographic groups.",[29],[29],"2023-07-28",{"date":314,"type":37},"2023-08-07",{"date":316,"type":21},"2024-08",{"date":318,"type":21},"2026-08",{"name":320,"class":321},"Power Life Sciences Inc.","INDUSTRY"]